LOGIN  |  REGISTER
Terns Pharmaceuticals

Veracyte to Participate in Upcoming Investor Conferences

October 30, 2024 | Last Trade: US$31.14 0.39 -1.24

SOUTH SAN FRANCISCO, Calif. / Oct 30, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences.

  • UBS Healthcare Conference – Rancho Palos Verdes, CA
    Fireside Chat on November 12th at 2:45 p.m. Eastern Time
  • Guggenheim Inaugural Healthcare Innovation Conference – Boston, MA
    Fireside Chat on November 13th at 3:00 p.m. Eastern Time
  • Wolfe Research Healthcare Conference – New York, NY
    Fireside Chat on November 19th at 1:40 p.m. Eastern Time
  • Stephens Annual Investor Conference – Nashville, TN
    Fireside Chat on November 20th at 4:00 p.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

Viking Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page